
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Complementary medicines filter Complementary medicines (7)
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Remove Medicines filter Medicines (2)
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (3) Apply Therapeutic goods regulation filter
- (-) Remove Medicines filter Medicines
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Complementary medicines filter Complementary medicines
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018